{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:44:04Z","timestamp":1777506244955,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.leukres.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T20:37:21Z","timestamp":1504211841000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line"],"prefix":"10.1016","volume":"61","author":[{"given":"Kelly","family":"Airiau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Turcq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Belloc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"August (5531)","key":"10.1016\/j.leukres.2017.08.014_bib0005","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2017.08.014_bib0010","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol. Med."},{"issue":"March (6)","key":"10.1016\/j.leukres.2017.08.014_bib0015","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"April (4)","key":"10.1016\/j.leukres.2017.08.014_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.leukres.2017.08.014_bib0025","doi-asserted-by":"crossref","first-page":"e78582","DOI":"10.1371\/journal.pone.0078582","article-title":"A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib","volume":"8","author":"Augis","year":"2013","journal-title":"PLoS One"},{"issue":"October (19)","key":"10.1016\/j.leukres.2017.08.014_bib0030","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1158\/1078-0432.CCR-08-0461","article-title":"Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells","volume":"14","author":"Okabe","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"August (8)","key":"10.1016\/j.leukres.2017.08.014_bib0035","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2010-10-313692","article-title":"Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells","volume":"118","author":"Gioia","year":"2011","journal-title":"Blood"},{"issue":"January (4)","key":"10.1016\/j.leukres.2017.08.014_bib0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor\u2013c-KIT pathway must be inhibited to enable apoptosis induced by BCR\u2013ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"Belloc","year":"2009","journal-title":"Leukemia"},{"issue":"Pt 2","key":"10.1016\/j.leukres.2017.08.014_bib0045","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1016\/j.clinthera.2009.11.015","article-title":"Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study","volume":"31","author":"Yin","year":"2009","journal-title":"Clin. Ther."},{"issue":"December (23)","key":"10.1016\/j.leukres.2017.08.014_bib0050","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure","volume":"12","author":"Luo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2017.08.014_bib0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","author":"Wong","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"June (24)","key":"10.1016\/j.leukres.2017.08.014_bib0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"May (5)","key":"10.1016\/j.leukres.2017.08.014_bib0065","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1345\/aph.1L570","article-title":"Once-daily dasatinib for treatment of patients with chronic myeloid leukemia","volume":"43","author":"Tyler","year":"2009","journal-title":"Ann. Pharmacother."},{"issue":"December (6)","key":"10.1016\/j.leukres.2017.08.014_bib0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis","volume":"14","author":"Shah","year":"2008","journal-title":"Cancer Cell"},{"issue":"October (16)","key":"10.1016\/j.leukres.2017.08.014_bib0075","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"issue":"June (1)","key":"10.1016\/j.leukres.2017.08.014_bib0080","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-12-3904","article-title":"Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis","volume":"73","author":"O\u2019Hare","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.08.014_bib0085","unstructured":"Bristol-Myers Squibb SPRYCEL\u00ae prescribing information (US), revised October 2010."},{"issue":"November (11)","key":"10.1016\/j.leukres.2017.08.014_bib0090","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3109\/10428194.2011.591013","article-title":"Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways","volume":"52","author":"Tang","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"January (1)","key":"10.1016\/j.leukres.2017.08.014_bib0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2010.06.030","article-title":"Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients","volume":"35","author":"Hayette","year":"2011","journal-title":"Leuk. Res."},{"issue":"October (10)","key":"10.1016\/j.leukres.2017.08.014_bib0100","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"Gromicho","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"March (3)","key":"10.1016\/j.leukres.2017.08.014_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"issue":"July (1)","key":"10.1016\/j.leukres.2017.08.014_bib0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"December (12)","key":"10.1016\/j.leukres.2017.08.014_bib0115","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u00ab real-time \u00bb quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2212 a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"December (12)","key":"10.1016\/j.leukres.2017.08.014_bib0120","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u00ab real-time \u00bb quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2212 a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"November (24)","key":"10.1016\/j.leukres.2017.08.014_bib0125","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.1073\/pnas.91.24.11752","article-title":"Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40","volume":"91","author":"Vayssiere","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"May (2)","key":"10.1016\/j.leukres.2017.08.014_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/excr.1997.3918","article-title":"Caspase activation is an early event in anthracycline-induced apoptosis and allows detection of apoptotic cells before they are ingested by phagocytes","volume":"240","author":"Durrieu","year":"1998","journal-title":"Exp. Cell Res."},{"issue":"April (8)","key":"10.1016\/j.leukres.2017.08.014_bib0135","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"June (24)","key":"10.1016\/j.leukres.2017.08.014_bib0140","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"November (22)","key":"10.1016\/j.leukres.2017.08.014_bib0145","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory philadelphia chromosome\u2013positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"April (2)","key":"10.1016\/j.leukres.2017.08.014_bib0150","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/187231210791292726","article-title":"siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors","volume":"4","author":"Haouala","year":"2010","journal-title":"Drug Metab. Lett."},{"issue":"December (23)","key":"10.1016\/j.leukres.2017.08.014_bib0155","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Fenouille","year":"2010","journal-title":"Cancer Res."},{"issue":"October","key":"10.1016\/j.leukres.2017.08.014_bib0160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.phrs.2015.08.010","article-title":"Fyn is an important molecule in cancer pathogenesis and drug resistance","volume":"100","author":"Elias","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"April (15)","key":"10.1016\/j.leukres.2017.08.014_bib0165","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/onc.2014.138","article-title":"Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy","volume":"34","author":"Elias","year":"2015","journal-title":"Oncogene"},{"issue":"March (9)","key":"10.1016\/j.leukres.2017.08.014_bib0170","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.18632\/oncotarget.7128","article-title":"FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia","volume":"7","author":"Chougule","year":"2016","journal-title":"Oncotarget"},{"issue":"August (8)","key":"10.1016\/j.leukres.2017.08.014_bib0175","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/bcj.2011.32","article-title":"Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib","volume":"1","author":"Kim","year":"2011","journal-title":"Blood Cancer J."},{"issue":"July (7)","key":"10.1016\/j.leukres.2017.08.014_bib0180","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Grosso","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"August (4)","key":"10.1016\/j.leukres.2017.08.014_bib0185","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10637-013-9929-8","article-title":"A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies","volume":"31","author":"Naing","year":"2013","journal-title":"Invest. New Drugs"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T12:02:19Z","timestamp":1620993739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":37,"alternative-id":["S0145212617304952"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.08.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}